One important source of evidence that the Branded Prescription Drug Fee has, in fact, contributed to recent rising drug prices is that, over the past
Arguments in defense of maintaining high drug prices to protect the strength of the drug industry misstate its vulnerability,” the authors wrote, adding that companies only spend 10% to 20% of their revenue on research and development. And this is a serious problem, the study concludes, because drug prices decline to 55% of their original brand name cost once there are two generics on the market and to 33% of original cost with five generics. We allow government-protected monopolies” for certain drugs, preventing generics from coming to market to reduce prices.
Pharmaceutical company representatives must submit samples of drugs and drug-related supplies for approval to the person at the medical facility to whom such responsibility is delegated under local policy, usually the Director. (5) Educational programs and associated materials regarding a drug, drug-related supply, or a new therapeutic indication for a drug that is already on the VANF but has not yet been reviewed by VA, must be submitted by the pharmaceutical company or pharmaceutical company representative to the VA medical facility 's Chief of Pharmacy Services or designee. Pharmaceutical companies in the United States are under constant pressure to develop and bring new drugs to market while observing the complex regulations issued by the Food and Drug Administration.
The Indian pharmaceutical company has been built from an industry that copies patent drugs and manufactures them inexpensively. Some of those large pharmaceutical companies are patient assistance” foundations, providing financial support to individuals in purchasing prescription medicines, but pharmaceutical companies are also huge givers of in-kind products, i.e. presumably their own drugs. In March 2001, 40 multi-national pharmaceutical companies brought litigation against South Africa for its Medicines Act , which allowed the generic production of antiretroviral drugs (ARVs) for treating HIV, despite the fact that these drugs were on-patent.
Ben Goldacre has argued that regulators - such as the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK, or the Food and Drug Administration (FDA) in the United States - advance the interests of the drug companies rather than the interests of the public due to revolving door exchange of employees between the regulator and the companies and friendships develop between regulator and company employees. The book Bad Pharma also discusses the influence of drug representatives, how ghostwriters are employed by the drug companies to write papers for academics to publish, how independent the academic journals really are, how the drug companies finance doctors' continuing education, and how patients' groups are often funded by industry.